NEW YORK (GenomeWeb News) – Knome announced today it has been selected to be a partner in the Illumina Genome Network.
As a result, customers in IGN will have access to preferential pricing for Knome's genome interpretation tools and services, the Cambridge, Mass.-based company said. Knome and Illumina will further integrate their data pipelines to accelerate turnaround times as part of the deal.
IGN will provide fully processed and summarized genome information from its whole genome and cancer analysis services to Knome, which will then provide subsequent interpretations, Scott Kahn, vice president and chief information officer for Illumina said.
Ari Kiiriki, Knome's VP of business development, said the two companies have often worked together on a case-by-case basis to provide researchers a complete sequencing and interpretation solution. Most recently Knome and Illumina collaborated on the 1,000 genomes asthma study by the Johns Hopkins University School of Medicine.
"Now that we have entered into a formal partnership, we look forward to working together to proactively identify researchers, drug developers, and clinics with interpretation bottlenecks in order to deliver a seamless end-to-end solution," Kiiriki said in a statement.